The U.S. depyrogenated sterile empty vials market size is likely to reach USD 3.5 billion by 2025

Thursday, November 15, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 14, 2018 /PRNewswire/ -- U.S. Depyrogenated Sterile Empty Vials Market Size, Share & Trends Analysis Report

By Product (2 ml, 5 ml, 10 ml, 20 ml), By End Use (Clinical Labs, Componding Pharmacies), And Segment Forecasts, 2018 - 2025Read the full report: The U.S. depyrogenated sterile empty vials market size is likely
to reach USD 3.5 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.2% during the forecast period. Technological advancements in pharmaceutical packaging process, growing funding by government organizations, and flourishing biologics market in the U.S. are some of the key trends escalating market growth. Stringent regulations laid by the government for parenteral are also poised to augment the market.Rising number of clinical labs in the country is resulting in an increased number of medical and diagnostic tests.This, in turn, is fueling the demand for depyrogenated sterile empty vials.Increasing number of compounding laboratories and research institutes in the U.S. is boosting the demand for these vials in the market. Moreover, continual growth in the pharmaceutical and biotechnology industry is further projected to drive the market.Increasing number of collaborations in order to achieve innovative packaging technology is also providing an upthrust to the market.Rising incidence of infectious & non-infectious diseases and growing number of clinical studies are translating into a greater demand for these vials.Besides this, the government is backing the promotion of pharmaceutical, medical, and biotechnological researches, which is anticipated to work in favor of the market.Further key findings from the report suggest:• More than 20 ml depyrogenated sterile empty vials emerged as the largest segment in terms of revenue in 2017 owing to rising incidence of infectious & non-infectious diseases and increasing investments in the biopharmaceutical sector• Others, which include pharmaceutical manufacturers and academic & research institutes, formed the most prominent end-use segment in 2017. The growth of the segment can be attributed to expanding base of medical & biotech research institutes and upswing in pharmaceutical manufacturing• Thermo Fisher Scientific, Inc.; Gerresheimer AG; SCHOTT AG; and DWK Life Sciences are the major players operating in the market. This market is considerably fragmented and market entry barrier is high.Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store